|
Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Begins phase I trial of HMPL-A83 for patients with advanced malignant neoplasms, in China. HMPL-A83 is an investigational novel IgG4-type humanized anti-CD47 monoclonal antibody. Malignant neoplasms are cancerous tumours. It has ‘significant’ potential to be used as a combination therapy with Hutchmed's existing portfolio, the firm says.
Current stock price: 212.35 pence, down 4.8% on Friday
12-month change: down 61%
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
